Amyloidosis Clinical Trials

15 studies are recruiting for amyloidosis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

   Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we …

   Stage

   Not phased

   Ages

   65 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT05577819 on ClinicalTrials.gov

2. Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

   The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on people who take it and have amyloidosis, and to determine the most effective dose of the drug. The study will have 2 phases (parts). The first phase of the study will test diffe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Vanderbilt Ingram Cancer Center, Nashville, Tennessee

   Locations

   3 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT05145816 on ClinicalTrials.gov

3. Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

   Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall a…

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   University of California, San Diego (UCSD) - Medical Center, La Jolla, California

   Locations

   104 in total

   Run by

   Eidos Therapeutics, a BridgeBio company

   See if you can join NCT06563895 on ClinicalTrials.gov

4. The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

   This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medica…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Run by

   Mayo Clinic

   See if you can join NCT07285044 on ClinicalTrials.gov

5. Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

   The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

   Stage

   Phase 4

   Ages

   18 to 80

   Site

   Washington University in St. Louis, St Louis, Missouri

   Run by

   Eidos Therapeutics, a BridgeBio company

   See if you can join NCT07695701 on ClinicalTrials.gov

6. A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

   The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .

   Stage

   Phase 2

   Ages

   18 and older

   Site

   GSK Investigational Site, Rochester, Minnesota

   Locations

   5 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT07224672 on ClinicalTrials.gov

7. A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

   Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Phoenix, Arizona

   Locations

   18 in total

   Run by

   Alexion Pharmaceuticals, Inc.

   See if you can join NCT07081646 on ClinicalTrials.gov

8. Dietary Reporting In The Amyloidoses

   The goal of this clinical trial is to learn about malnutrition and weight loss in patients with Amyloidosis. The main question it aims to answer is: Is it feasible to use a low-cost nutrition-based application (apps) for use on a smartphone to obtain detailed information on caloric intake in Amyloi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Run by

   Barbara Ann Karmanos Cancer Institute

   See if you can join NCT05738005 on ClinicalTrials.gov

9. Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

   Background: Anakinra is a drug used to treat people with certain diseases that affect their immune systems. Sometimes anakinra can cause proteins under the skin to clump together. These clumps are called amyloidosis; they can spread to other organs. The only way to diagnose amyloidosis is to remove…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT06974877 on ClinicalTrials.gov

10. Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

    This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in cardiac amyloidosis 2) Evaluate extracardiac uptake 3) identify and characterize the distribution …

    Stage

    Phase 2

    Ages

    40 to 90

    Site

    Oregon Health & Science University, Portland, Oregon

    Run by

    Oregon Health and Science University

    See if you can join NCT05758493 on ClinicalTrials.gov

11. Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

    This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma (cohort A) and amyloidosis (cohort B).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT04991103 on ClinicalTrials.gov

12. A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography

    This is a prospective case control study to determine the feasibility and utility of myocardial stiffness assessment by cardiac magnetic resonance elastography (MRE) in patients with cardiac amyloidosis.

    Stage

    Not phased

    Ages

    20 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT07216469 on ClinicalTrials.gov

13. A Study Of MCG In Cardiac Amyloidosis

    The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT07218705 on ClinicalTrials.gov

14. Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

    The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at …

    Stage

    Not phased

    Ages

    50 and older

    Site

    Kirklin Clinic of UAB Hospital, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT05556928 on ClinicalTrials.gov

15. Registry for Adults With Plasma Cell Disorders (PCD's)

    The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives includ…

    Stage

    Not phased

    Ages

    18 and older

    Site

    North Carolina Cancer Hospital, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT03717844 on ClinicalTrials.gov